Your session is about to expire
← Back to Search
Pembrolizumab for Diffuse Large B-Cell Lymphoma
Study Summary
This trial is testing a new immunotherapy drug for people with a certain type of lymphoma that has come back or didn't respond to other treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated for an infection.I have had or currently have lung inflammation treated with steroids.I have a history of Hepatitis B or active Hepatitis C.I agree to use contraception and not donate sperm for 120 days after my last treatment dose.You have a severe allergic reaction (Grade 3 or higher) to pembrolizumab or any of its ingredients.I have an active tuberculosis infection.I had radiotherapy over a week ago and have no side effects needing steroids.I have an autoimmune disease but haven't needed strong medication for it in the last 2 years.I have been diagnosed with HIV.I have fully recovered from any major surgery before starting the study treatment.I've had cancer treatment within the last 4 weeks and have mostly recovered from side effects.I have been diagnosed with primary mediastinal or gray zone lymphoma.I have not received a live vaccine in the last 30 days.I am fully active or restricted in physically strenuous activity but can do light work.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I had a stem cell transplant over 5 years ago, with no severe GVHD or current treatment for chronic GVHD.I have stable brain metastases and haven't needed steroids for 14 days.I have been treated with specific immune therapy drugs before.My lymphoma is high-grade or has specific gene changes.I have had at least two treatments for my condition, or refused a specific transplant.My kidney function, measured by creatinine or GFR, is within the required range.My kidney function is normal.My blood clotting tests are within safe limits, even if I'm on blood thinners.I have a history or current evidence of a medical condition.My recent tests show my organs are functioning well.My lymphoma has a PD-L1 gene change.I had CAR T cell therapy or a transplant over 5 years ago without severe side effects.I have a biopsy sample available from my most recent cancer relapse.I have another cancer that is getting worse or was treated in the last 3 years.I have had a solid organ transplant.I am not pregnant, not breastfeeding, and meet one of the specific conditions.I am 18 or older with a confirmed diagnosis of DLBCL.I have a tumor that can be measured by CT scan, larger than 15mm by 10mm.My liver is functioning properly.
- Group 1: Pembrolizumab Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other avenues of research have been explored with Pembrolizumab?
"Currently, there are 1000 trials running that study Pembrolizumab. 122 of those studies are in the third and final stage of clinical trials. The majority of these trials take place in Houston, Texas; however, there are 36034 locations across the world where these trials are taking place."
Can patients currently enroll in this research study?
"The most recent information available on clinicaltrials.gov suggests that this study is still recruiting patients. The posting date was September 4th, 2019 and the last edit was made on January 5th, 2021. Up to 29 people from a single location can participate in the trial."
What is the maximum capacity for participants in this experiment?
"The latest information available on clinicaltrials.gov verifies that this study is still seeking enrolment from potential participants. The listing for the trial was first published on September 4th, 2019 and updated as recently as January 5th, 2021. Currently, 29 people are needed to fill the vacant spots at a single location."
Has Pembrolizumab been federally recognized as a safe treatment?
"Pembrolizumab has received a score of 2 for safety. This is due to the fact that it is only in Phase 2, meaning while there have been studies conducted observing its safety, none have yet looked at whether or not it is effective."
What are the conditions that Pembrolizumab is indicated to treat?
"Pembrolizumab is approved to treat malignant neoplasms, but it has also shown promise in treating conditions such as unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
Share this study with friends
Copy Link
Messenger